Compare FIG & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIG | DVA |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | United States |
| Employees | 1886 | N/A |
| Industry | Computer Software: Prepackaged Software | Misc Health and Biotechnology Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 9.9B |
| IPO Year | N/A | 2002 |
| Metric | FIG | DVA |
|---|---|---|
| Price | $19.11 | $198.63 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 13 | 4 |
| Target Price | $50.50 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 14.6M | 824.0K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.87 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $31.18 | $3.85 |
| Revenue Next Year | $20.22 | $3.07 |
| P/E Ratio | ★ N/A | $69.74 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $16.60 | $101.00 |
| 52 Week High | $114.29 | $202.69 |
| Indicator | FIG | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 81.52 |
| Support Level | $17.13 | $145.58 |
| Resistance Level | $21.45 | N/A |
| Average True Range (ATR) | 1.06 | 7.01 |
| MACD | 0.36 | 4.94 |
| Stochastic Oscillator | 54.39 | 93.02 |
Figma Inc is engaged in transforming ideas into digital products and experiences. The group focuses on the entire software creation lifecycle, enabling it to quickly launch new products on Figma's browser-based platform and reinforcing its belief that design extends well beyond a single step or role. The company adopts an expansive view, as design is more than how something looks, feels, or works. It derives its revenue from sales of subscriptions for access to its platform.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.